Effects of adalimumab (Humira) on biomarkers in skin and synovial tissue in patients with psoriatic arthritis

Trial Profile

Effects of adalimumab (Humira) on biomarkers in skin and synovial tissue in patients with psoriatic arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms ADAPs
  • Most Recent Events

    • 01 Aug 2009 Status changed from recruiting to completed based on publication of results
    • 01 Aug 2009 Results were published in the Annals of the Rheumatic Diseases.
    • 03 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top